Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11398380 | 1.00 | CYP2B6 (1.00) | CYP2B6CHRM2CHRM1HTR1AOPRM1 | |
| SCHEMBL19011533 | 0.98 | CYP2B6 (0.96) | CYP2B6CHRM2CHRM1HTR1AOPRM1 | |
| SCHEMBL30364035 | 0.93 | CYP2B6 (0.88) | CYP2B6CHRM2CHRM1OPRM1KCNH2 | |
| SCHEMBL25533428 | 0.83 | CYP2B6 (0.70) | CYP2B6CHRM2CHRM1OPRM1KCNH2 | |
| SCHEMBL8354397 | 0.81 | CYP2B6 (0.68) | CYP2B6LMNAACHEHRH3SIGMAR1 | |
| SCHEMBL17810248 | 0.80 | CYP2B6 (0.67) | CYP2B6CHRM2CHRM1HTR1AOPRM1 | |
| SCHEMBL12665881 | 0.79 | CYP2B6 (0.66) | CYP2B6LMNAACHESIGMAR1 | |
| SCHEMBL2696963 | 0.79 | CYP2B6 (0.66) | CYP2B6OPRM1LMNAACHECYP3A4 | |
| SCHEMBL2697321 | 0.79 | CYP2B6 (0.66) | CYP2B6CHRM2CHRM1HTR1AKCNH2 | |
| SCHEMBL4701627 | 0.79 | CYP2B6 (0.66) | CYP2B6CHRM2CHRM1HTR1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334175-B1 | PHENYL-SUBSTITUTED BICYCLOOCTANE 1,3 DIONE DERIVATIVES | BAYER IP GMBH (DE) | 2017-03-01 | — | — | EP | claimed |
| EP-2635550-B1 | PHENYL-SUBSTITUTED BICYCLOOCTANE-1,3-DIONE-DERIVATIVES | BAYER IP GMBH (DE) | 2016-01-27 | — | — | EP | claimed |
| EP-2534147-B1 | SPIROHETEROCYCLIC-SUBSTITUTED TETRAMIC ACID DERIVATIVES | BAYER IP GMBH (DE) | 2015-06-17 | — | — | EP | claimed |
| US-20200384188-A1 | SYSTEMS, DEVICES, FORMULATIONS AND METHODS FOR CONTROLLED DRUG DELIVERY | BEXSON BIOMEDICAL, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3710079-A1 | SYSTEMS, DEVICES, FORMULATIONS AND METHODS FOR CONTROLLED DRUG DELIVERY | Bexson Biomedical, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-109526219-A | Benzsulfamide and its purposes as therapeutic agent | 泽农医药公司 | 2019-03-26 | — | — | CN | disclosed |
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-8088771-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | CYP2B6 2859/4885CHRM2 4630/4885CHRM1 4791/4885 |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | CYP2B6 2859/4885CHRM2 4630/4885CHRM1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.